Quarterly report [Sections 13 or 15(d)]

Accounts Payable and Accrued Expenses (Details)

v3.26.3
Accounts Payable and Accrued Expenses (Details) - USD ($)
$ in Thousands
 1 Months Ended 9 Months Ended
Feb. 28, 2026
Sep. 30, 2026
Dec. 31, 2025
Dec. 31, 2024
Accounts Payable and Accrued Expenses [Line Items]        
Accounts payable   $ 12,909 $ 14,238  
Accrued expenses:        
Professional fees   1,907 1,055  
Salaries, bonus and related benefits   5,956 7,880  
Research and development   1,134 277  
Accrued partner company royalties payable   2,210 1,805  
Accrued partner company coupons and rebates   24,510 16,547  
Partner company return reserve   3,329 2,177  
Other   4,673 3,146  
Total accounts payable and accrued expenses   56,628 $ 47,125  
Mustang | uBriGene (Boston) Biosciences, Inc.        
Accrued expenses:        
Other   1,300   $ 1,400
Accrued Interest       $ 100
Upfront payment   $ 100    
Interest rate on outstanding liability   5.00%    
Mustang | uBriGene (Boston) Biosciences, Inc. | Maximum        
Accrued expenses:        
Net assets   $ 20,000    
Mustang | uBriGene (Boston) Biosciences, Inc. | If Mustang's net assets are below $20 million        
Accrued expenses:        
Additional payment period   6 months    
Net assets   $ 20,000    
Cyprium        
Accrued expenses:        
Consideration received $ 205,000      
Cyprium | PRV APA        
Accrued expenses:        
Consideration received $ 205,000      
Cyprium | PRV APA | Eunice Kennedy Shriver National Institute of Child Health and Human Development        
Accrued expenses:        
Percentage of proceeds obligated to pay 20.00%      
Gross proceeds $ 41,000